Management Team

Daniel G. Chain, Ph.D.
Chief Executive Officer and Chairman

Dr. Chain formed Intellect in April 2005 and has served as our Chairman and Chief Executive Officer since October 2005.  Dr. Chain was previously the President and CEO of Mindset BioPharmaceuticals, a private company he founded in 1999.

Dr. Chain is the inventor of the Company’s ANTISENILIN® technology for the treatment and prevention of Alzheimer’s disease which underlies products in Phase 1, Phase 2 and Phase 3 clinical trials by major pharmaceutical companies that have purchased licenses from Intellect Neurosciences for the commercialization of those products. Patents in relation to Dr. Chain’s invention have been granted in Europe, Japan and several other countries and are pending in the United States.  Dr. Chain is also the inventor of a patent recently granted in Europe concerning the use of insulin sensitizers for the prevention and treatment of memory loss and dementia.  Dr. Chain has spend more than a decade devoted to developing innovative approaches aimed at slowing, arresting or preventing Alzheimer’s  disease.  Collectively, these different approaches drive Intellect Neuroscience’s internal drug pipeline that is backed by intellectual property assets across diversified technologies.  Dr. Chain has authored numerous scientific research publications in peer-reviewed journals and his broad expertise is increasingly drawing positive attention in the media featuring in articles and radio interviews to discuss new developments in the Alzheimer's field and the progress being made by Intellect Neurosciences.  Dr. Chain is a member of the Royal Society of Medicine and the Society for Neuroscience.  Dr. Chain obtained his B.Sc., with honors, in Biochemistry from the Institute of Biology in London and obtained his Ph.D. in Biochemistry from the Weizmann Institute of Science in Israel. He trained as a post-doctoral research fellow at the Center for Neurobiology and Behavior at Columbia University College of Physicians and Surgeons in New York where he collaborated with Nobel Laureate, Professor Eric Kandel.

Elliot M. Maza, J.D., CPA
Chief Financial Officer

Mr. Maza has served as our Chief Financial Officer since March 2007. He served as Executive Vice President and Chief Financial Officer from May 2006 until March 2007. From December 2003 to May 2006 Mr. Maza was Chief Financial Officer of Emisphere Technologies, Inc., a publicly held biopharmaceutical company specializing in oral drug delivery. He was a partner at Ernst and Young LLP from March 1999 to December 2003 and an investment banker at Goldman Sachs, Inc., JP Morgan Securities, Inc. and Bankers Trust Securities, Inc. at various times during April 1989 to March 1999. Mr. Maza practiced law at Sullivan and Cromwell in New York from September 1985 to April 1989. Mr. Maza serves on the Board of Directors and is Chairman of the Audit Committee of Apollo Solar Energy, Inc., a Chinese producer of material used to manufacture solar cells. Mr. Maza received his B.A. degree from Touro College in New York and his J.D. degree from the University of Pennsylvania Law School. He is a licensed C.P.A. in the states of New Jersey and New York and is a member of the New York State Bar.